胃癌腹膜转移的机制研究进展综述

作者

  • 杨成 遵义医科大学基础医学院组胚教研室，中国 贵州 遵义 563000 作者
  • 游贤锋 遵义医科大学基础医学院组胚教研室，中国 贵州 遵义 563000 作者
  • 李浩艺 遵义医科大学基础医学院组胚教研室，中国 贵州 遵义 563000 作者
  • 聂宇帆 遵义医科大学基础医学院组胚教研室，中国 贵州 遵义 563000 作者
  • 许强 遵义医科大学第二附属医院泌尿外科，中国 贵州 遵义 563000 作者
  • 梁娜 遵义医科大学基础医学院组胚教研室，中国 贵州 遵义 563000 作者

关键词:

胃癌, 腹膜转移, 分子机制, 肿瘤微环境, 免疫逃逸

摘要

胃癌腹膜转移是导致患者预后不良的关键因素，其发生机制涉及多步骤、多因素的复杂生物学过程。近年来，随着分子生物学和免疫学研究的深入，肿瘤细胞脱落与侵袭、腹膜微环境适应与重塑、血管与淋巴管生成以及免疫逃逸等环节在GCPM中的作用逐渐明晰。本文系统综述了胃癌腹膜转移的核心机制，重点探讨了信号通路异常、细胞外基质重塑及免疫抑制微环境在促进肿瘤细胞定植与生长中的关键作用。同时，分析了现有研究存在的不足，如机制间交互作用的复杂性及临床转化瓶颈。本文旨在为胃癌腹膜转移的早期诊断标志物筛选和靶向治疗策略开发提供理论依据，并展望了基于多组学整合和免疫微环境调控的未来研究方向。

参考

[1] Di Giorgio A, Gerardi C, Abatini C, et al. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)-a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO[J]. Trials, 2022, 23(1): 969-980.

[2] 朱思颖,赵红.胃癌腹膜转移防治进展[J].临床荟萃,2020,35(12):1142-1147.

[3] 赵宏伟,刘宏斌,李文惠.胃癌腹膜转移机理研究现状[J].现代肿瘤医学,2009,17(5):978-981.

[4] 胡祥.胃癌的腹膜转移及其对策[J].中华胃肠外科杂志,2007,10(5):417-419.

[5] Yu D, Chang Z, Liu X, et al. Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253[J]. Cell Cycle, 2023, 22(6): 705-717.

[6] 薛侃.腹膜转移——胃癌诊治的难点 [J].癌症康复,2023(2):19-20.

[7] Eftimie MA, Potlog G, Alexandrescu ST. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review[J]. Medicina (Kaunas), 2023, 59(2): 255-276.

[8] Nagamura Y, Miyazaki M, Nagano Y, et al. SHP2 as a Potential Therapeutic Target in Diffuse-Type Gastric Carcinoma Addicted to Receptor Tyrosine Kinase Signaling[J]. Cancers (Basel), 2021, 13(17): 4309-4323.

[9] Nagamura Y, Miyazaki M, Nagano Y, et al. PLEKHA5 regulates the survival and peritoneal dissemination of diffuse-type gastric carcinoma cells with Met gene amplification[J]. Oncogenesis, 2021, 10(3): 25-38.

[10] 刘骏强,徐岷.上皮-间充质转化在胃癌中的研究进展[J].癌症进展,2019,17(18):2124-2127.

[11] 李晓梅,魏育才,唐富天,等.上皮-间充质转化与能量代谢对胃癌转移的影响[J].兰州大学学报（医学版）,2022,48(1):67-71.

[12] 姜蕊,赵春明,宋美娟,等.RNA干扰抑制Snail表达对于胃癌细胞上皮间充质转化以及体外侵袭的影响[J].中国组织化学与细胞化学杂志,2010,19(5):483-487.

[13] Kim J, Shin K, Lee SH, Kim IH. Slug and CD133 expression are associated with peritoneal carcinomatosis and survival in gastric cancer[J]. J Gastrointest Oncol, 2021, 12(4): 1326-1337.

[14] 徐群芳,谈文龙,赵锐.转化生长因子β诱导肿瘤微环境改变促进胃癌NCI-N87细胞上皮间充质转化[J].国际药学研究杂志,2014(6):686-692.

[15] Zhang F, Yan Y, Cao X, et al. TGF-β-driven LIF expression influences neutrophil extracellular traps (NETs) and contributes to peritoneal metastasis in gastric cancer[J]. Cell Death Dis, 2024, 15(3): 218-230.

[16] 解刚强,范永刚,王伟,等.转化生长因子-β1通过诱导Wnt信号通路调节胃癌细胞上皮-间充质转化[J].中华实验外科杂志,2018,35(11):2079-2081.

[17] Ogawa S, Kubo H, Murayama Y, et al. Matrix metalloprotease-14 is a target enzyme for detecting peritoneal metastasis in gastric cancer[J]. Photodiagnosis Photodyn Ther, 2021, 35: 102420-102427.

[18] He C, Zhou Z, Ye J, et al. TGF-βI/FERMT2/COL6A1 Reciprocal Loop Drives Tumor-Stroma Crosstalk and Promotes Peritoneal Metastasis in Gastric Cancer[J]. Int J Biol Sci, 2025, 21(13): 5859-5873.

[19] 吕志栋,孔滨,刘相萍,等.转化生长因子β1对间皮细胞上皮-间质表型转化的调控及对胃癌腹膜转移的影响[J].中华胃肠外科杂志,2015(1):54-57.

[20] 王静远,王小娟,章程,等.腹腔微环境与胃癌腹膜转移关系的研究进展[J].中华消化外科杂志,2020,19(9):1004-1008.

[21] 陆瑞祺,俞继卫,姜波健.趋化因子及其受体与胃癌的关系[J].中国普外基础与临床杂志,2010,17(6):627-632.

[22] Miyamoto S, Nagano Y, Miyazaki M, et al. Integrin α5 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinoma[J]. Cancer Lett, 2022, 526: 335-345.

[23] Suzuki H, Goto N, Tanaka T, et al. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas[J]. Antibodies (Basel), 2023, 12(3): 45-61.

[24] 杨建桥,姜可伟,王杉.免疫治疗在胃癌腹膜转移中的应用和挑战[J].中华胃肠外科杂志,2025,28(5):557-563.

[25] Arjunan A, Venkatraman G, Joseph LD. Mitochondrial homeostasis and their impact on gastric carcinoma[J]. Int J Biochem Cell Biol, 2025, 186: 106827-106838.

[26] Li LM, Feng LY, Liu CC, et al. Can visceral fat parameters based on computed tomography be used to predict occult peritoneal metastasis in gastric cancer? [J]. World J Gastroenterol, 2023, 29(15): 2310-2321.

[27] Ortiz N, Delgado-Carazo JC, Díaz C. Importance of Mevalonate Pathway Lipids on the Growth and Survival of Primary and Metastatic Gastric Carcinoma Cells[J]. Clin Exp Gastroenterol, 2021, 14: 217-228.

[28] 王官成.VEGF在肿瘤血管及淋巴管生成中的研究[J].中国现代普通外科进展,2013,16(3):240-243,252.

[29] 刘贤忠,张丽婷,童卫泉,等.肿瘤相关巨噬细胞在血管生成和淋巴管生成中的研究进展[J].细胞与分子免疫学杂志,2016,32(2):280-283.

[30] Kang D, Kim IH. Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer[J]. Biomedicines, 2022, 10(6): 1376-1392.

[31] 青晓艳,徐义全,刘定义,等.促血管生成素家族在恶性肿瘤间质微血管和淋巴管生成中的作用[J].中华临床医师杂志（电子版）,2013(15):7096-7098.

[32] 李鹏(综述),申翼(审校).肿瘤的淋巴管生成和淋巴血管重塑[J].医学研究生学报,2015(6):646-649.

[33] 王仰坤,代爱军,杨成轩,等.胃癌组织淋巴管和血管生成与增殖细胞关系的研究[J].实用肿瘤学杂志,2009,23(4):332-335,393.

[34] Shen X, Liu H, Zhou H, et al. Galectin-1 promotes gastric cancer peritoneal metastasis through peritoneal fibrosis[J]. BMC Cancer, 2023, 23(1): 559-571.

[35] Huang C, Jiang Z, Shen X, et al. Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil[J]. iScience, 2026, 29(6): 115908-115927.

[36] Chen XJ, Wei CZ, Lin J, et al. Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis[J]. Biomedicines, 2023, 11(7): 2003-2014.

[37] Kim H, Kwon M, Lee SK, et al. Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis[J]. J Gastric Cancer, 2025, 25(4): 605-620.

[38] Idiz UO, Mutlu I, Barut Y, et al. Immunological Insights into Peritoneal Carcinomatosis for Gastrointestinal Malignancies: The Role of Soluble Factors in Malignant Ascites[J]. Biomedicines, 2026, 14(5): 1141-1153.

[39] Lewis CR, Dadgar N, Yellin SA, et al. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment[J]. Cancers (Basel), 2023, 15(20): 5107-5122.

[40] Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer[J]. J Immunother Cancer, 2021, 9(6): e002195-e002208.

[41] Takahashi K, Kurashina K, Yamaguchi H, et al. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer[J]. Front Immunol, 2022, 13: 969468-969477.

[42] Li Y, Jiang L, Chen Y, et al. Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis[J]. Gastric Cancer, 2024, 27(3): 519-538.

[43] Wang Y, Ma C, Li X, et al. Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review[J]. J Transl Med, 2025, 23(1): 623-642.

[44] Che K, Luo Y, Song X, et al. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer[J]. EMBO Mol Med, 2024, 16(2): 251-266.

[45] Zhao J, Ji C, Sun J, et al. Hyaluronic acid-CD44 signaling defines therapeutic resistance and immunosuppressive microenvironment in peritoneal metastasis of gastric cancer[J]. J Immunother Cancer, 2026, 14(3): e014179-e014197.

[46] Wang Y, Guo T, Xing X, et al. The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1/PD-1 axis[J]. Mol Oncol, 2025, 19(5): 1532-1545.

[47] Li Y, Zheng Y, Huang J, et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases[J]. Gut, 2025, 74(3): 350-363.

下載

已出版

2026-08-12

期次

Volume 1, Issue 1, 2026

栏目

文章